Electrochemical Aptamer-Based Biosensor Developed to Monitor PCA3 and PSA Released by Prostate Cancer Cells

Abstract

1. Introduction Detection of prostate cancer (PCa) in the early stage of the disease is fundamental for the prevention of metastases and for the initiation of treatment, which may bring greater chance of patient cured; so several research groups have sought the manufacture of a simple and non-invasive methodology [1]. The early diagnosis relies on prostate specific antigen (PSA) serum test, even if it showed clear limits [2]. Recently, prostate cancer gene 3 (PCA3), a non-coding mRNA which is overexpressed in tumor cells when compared with noncancerous prostate tissue [3]. Here, we report a new method for detection of prostate cancer-specific antigen 3 (PCA3) and prostate specific antigen (PSA) released by cancer cells using an aptasensor. Electrochemical impedance spectroscopy (EIS), SEM and EDS were used to evaluate biosensor surface. 2. Experimental Part The aptamers were modified through Biosearch Technologies at 5′-terminus in C6-disulfide linker to have it bond to the gold electrode; and at 3′-end in methylene blue (MB) (as redox probe) to perform the electrochemical analysis, which was followed by the HPLC purification process to remove truncated-synthesis products and to enrich the purity of the aptamer sequences. Aptamer immobilization was done by incubation of 1 μM thiolated aptamer on the top of the gold-coated silicon electrode overnight, in the dark, at 4°C. Subsequently, the electrodes were washed with PBS and a backfilling consisted of 3 mM of MCH aqueous solution for 30 minutes was done to displace the nonspecifically adsorbed aptamer molecules and to passivate the electrode surface [26]. Finally, the electrodes were once more rinsed with PBS to remove MCH excesses. The electrochemical characterization was done in a potentiostat μAutolabIII (Metrohn, NL), using a three-electrode system, which consisted of Ag/AgCl (3M KCl), as reference electrode; Pt wire, as a counter electrode; and gold-coated silicon wafer, as a working electrode. The prostate cell lines used were normal human prostate cells (RWPE-1; ATCC® CRL-11™), androgen-sensitive human prostate cancer cells (LNCaP; ATCC® CRL-1740™), and androgen-independent human prostate cancer cells (PC-3; ATCC® CRL-1435™). The three lineages were chosen to better understand PCA3 and PSA production patterns by different cell types. 3. Results and Discussion The gold-coated silicon wafe electrode was analyzed by SEM and EDS, which acts as working electrode and substrate to anchor the thiolated aptamer on the surface. By using square wave voltammetry, the present aptasensor was able of monitoring the PCA3 and PSA released from prostate cells (normal and cancerous). The PSA and PCA3 detection limits were 1 ng/mL and 9.2 ng/mL, respectively, at linear range up to 150 ng/mL, and it was also able to detect both biomarker even in presence of several interfering compounds (UA, AA, BSA and MUC1). In addition, the herein developed aptasensor was able to verify, at accurate and robust response, the patterns of the PCA3 and PSA released by different cell lines (RWPE-1, LNCaP and PC3). The detection of PSA and PCA3 by aptasensor agree with the cell lineage type, the LNCaP is an androgen-dependent lineage. In this way, an overexpressed both biomarkres was release was verified [49,50] and it can be compared to early-stage patients. On the other hand, the PC3 cells PSA and PCA3 releasing was nearly background signal, demonstrating almost absent production of studied targets, the PC3 lineage is androgen-independent which can be compared to advanced-disease patients. Funding This work has been supported by a grant from FAPESP-Brazil, CNPq and Capes.